<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040373</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTR02-010</org_study_id>
    <nct_id>NCT05040373</nct_id>
  </id_info>
  <brief_title>Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program</brief_title>
  <official_title>Patisiran-LNP Pregnancy Surveillance Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy&#xD;
      complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">October 12, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 12, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Major Congenital Malformations</measure>
    <time_frame>From 12 weeks prior to last dose of patisiran through one year after birth (Up to 21 months)</time_frame>
    <description>Major congenital malformations will be classified according to the European Concerted Action on Congenital Anomalies and Twins (EUROCAT) and Metropolitan Atlanta Congenital Defects Program (MACDP) classification systems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Minor Congenital Malformations</measure>
    <time_frame>From 12 weeks prior to last dose of patisiran through one year after birth (Up to 21 months)</time_frame>
    <description>Minor congenital malformations will be classified classified according to the EUROCAT and MACDP classification systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Pregnancy Outcomes</measure>
    <time_frame>From 12 weeks prior to last dose of patisiran through one year after birth (Up to 21 months)</time_frame>
    <description>Pregnancy outcomes are defined as live birth, spontaneous abortions, stillbirths, elective abortions, molar or pregnancy, ectopic pregnancy, preterm births, and maternal death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Other Adverse Fetal/Neonatal/Infant Outcomes</measure>
    <time_frame>From 12 weeks prior to last dose of patisiran through one year after birth (Up to 21 months)</time_frame>
    <description>Other adverse fetal/neonatal/infant outcomes are defined as low birth weight, failure to thrive, small for gestational age, postnatal growth and development, neonatal, and perinatal, or infant death.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hereditary Transthyretin-mediated (hATTR) Amyloidosis</condition>
  <condition>Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Patisiran</arm_group_label>
    <description>Pregnant women exposed to commercial patisiran-LNP (ONPATTRO) during the 12 weeks prior to their last menstrual period (LMP) or at any time during pregnancy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any woman exposed to patisiran-LNP 12 weeks prior to their last menstrual period (LMP) or&#xD;
        at any time during pregnancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documentation that the patient was exposed to patisiran-LNP at any point starting from&#xD;
             12 weeks before LMP or at any point during pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There are no exclusion criteria for participation in this program.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-ALNYLAM</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-256-9526</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary neuropathic amyloidosis</keyword>
  <keyword>Familial amyloidosis</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>Amyloidosis senile</keyword>
  <keyword>Cardiac amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

